Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : Analyse comorbide des troubles neurodéveloppementaux et de l’épilepsie Hor26/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Analyse comorbide des troubles neurodéveloppementaux et de l’épilepsie
Neurodevelopmental disorders (NDDs) including autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) are clinically heterogeneous, often co-occur, affect ~15% of the EU population; and are associated with somatic illnesses (e.g. epilepsy, autoimmune and gastrointestinal disease) that lead to a significant increase in morbidity and mortality. For instance in ASD the combination of ID and epilepsy is associated with a reduction in lifespan of ~ 20 years; and an economic cost that is greater than cancer, stroke, or dementia. Yet, the research spend on NDDs is less than 1% of those disorders. Hence, we lack effective new treatments for NDDs and do not understand why they co-occur. There is hope, however. Recent evidence shows that rare genetic variants increasing risk for NDDs are shared, converge on final common pathways (e.g. synaptic plasticity, glutamate and GABA neurotransmission, and excitation/inhibition imbalance), and a key role is likely played by immune dysregulation. CANDY’s innovation is to test, for the first time, if NDDs, and their common mental and somatic multi-morbidity, are caused by a combination(s) of common and rare genetic variants and immune activation acting at different ‘sensitive periods’. Our multi-disciplinary team of world leading academics, patient organizations and SMEs will cost-effectively leverage existing EU-funded studies to 1) identify novel mechanisms underpinning NDDs and their multi-morbidity, 2) develop new strategies for prevention and treatment, 3) deliver novel biomarkers to guide early diagnosis, stratification and/or treatment monitoring, and 4) provide open-access databases, translational test batteries, and tools and targets for valorisation. Together we will transform the landscape for people with NDDs and make possible personalized medicine approaches that target particular mechanisms, in specific subgroups of individuals and at different life stages.
| ADD Information Services | 30 000 € |
| ARTTIC INNOVATION GmbH | 312 087 € |
| Arttic | 37 913 € |
| Assistance Publique Hopitaux de Paris | 264 580 € |
| Autisme-Europe Aisbl | 30 000 € |
| Birkbeck College - University of London | 125 000 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 500 000 € |
| Institut National de la Sante et de la Recherche Medicale | 385 420 € |
| Institut Pasteur | 425 000 € |
| Karolinska Institutet | 300 000 € |
| King's College London | 825 000 € |
| Noldus Information Technology B.V. | 200 000 € |
| Rijksuniversiteit Groningen | 250 000 € |
| Stichting Radboud Universitair Medisch Centrum | 1 615 000 € |
| 0,00 € | |
| UNIVERSITAET ULM | 150 000 € |
| 250 000 € | |
| Universiteit Gent | 300 000 € |
https://cordis.europa.eu/project/id/847818
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ADD Information Services - Financement de l’UE (6 000 000 €) : Analyse comorbide des troubles neurodéveloppementaux et de l’épilepsie"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
